Q3 2024 13F Holders as of 30 Sep 2024
-
Type / Class
-
Equity / Common Stock, par value $0.0001 per share
-
Shares outstanding
-
1,079,784,035
-
Total 13F shares
-
68,558,924
-
Share change
-
+6,579,019
-
Total reported value
-
$255,147,599
-
Put/Call ratio
-
78%
-
Price per share
-
$3.72
-
Number of holders
-
172
-
Value change
-
+$21,750,911
-
Number of buys
-
81
-
Number of sells
-
68
Institutional Holders of ImmunityBio, Inc. - Common Stock, par value $0.0001 per share (IBRX) as of Q3 2024
As of 30 Sep 2024 ImmunityBio, Inc. - Common Stock, par value $0.0001 per share (IBRX) had 172 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions held a total of 68,558,924 shares of stock of the company.
Largest 10 holders included VANGUARD GROUP INC, BlackRock, Inc., STATE STREET CORP, GEODE CAPITAL MANAGEMENT, LLC, MORGAN STANLEY, BANK OF AMERICA CORP /DE/, UBS AM, a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC, GOLDMAN SACHS GROUP INC, CHARLES SCHWAB INVESTMENT MANAGEMENT INC, and NORTHERN TRUST CORP.
This table shows 172 institutional shareholders of the security as of 30 Sep 2024.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.